Alpha Lipoic Acid Neuropathy Meta-analysis: What the Evidence Says

Quick Answer

Alpha Lipoic Acid Neuropathy Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 research article, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Although ALA is not considered a first-line analgesic for neuropathic pain in contemporary guideline-based meta-analyses,it has shown moderate efficacy in reducing neuropathic symptom burden and improving sensory function in diabetic neuropathy, particularly when administered intravenously.Oral formulations have also demonstrated benefit in trials with longer treatment durations, albeit with reduced effect sizes. [Zárate Edith (2026); evidence level 4]
• Furthermore, our group previously reported a Phase 1 crossover trial showing that co-administration of pregabalin and thioctic acid (fixed-dose, PGB 80 mg + ALA 400 mg) did not result in clinically relevant pharmacokinetic interactions, supporting the feasibility of a fixed-dose combination strategy. [Zárate Edith (2026); evidence level 4]
• During the study period, 3 patients in the roflumilast group dropped out secondary to non-adherence (n=2) and the development of thyroid cancer (n=1), and 3 patients in the alpha-lipoic acid group also dropped out as a result of non-compliance. [Elsharab Asmaa (2025); evidence level 4]
• Roflumilast treatment reduced FBG from 140 (17) to 118 (11) (P1<0.001), while alpha-lipoic acid reduced FBG from 139 (12) to 123 (10) (P1<0.001). [Elsharab Asmaa (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For alpha lipoic acid neuropathy meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Z&#225;rate Edith (2026). Combination therapy with pregabalin and thioctic acid offers safer pain control in diabetic neuropathy: a multicenter, double-blind, non-inferiority trial. DOI: 10.1093/braincomms/fcag058. PMCID: PMC12971004. PMID: 41809439. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12971004/
• Elsharab Asmaa (2025). Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study. DOI: 10.2147/DMSO.S548285. PMCID: PMC12621582. PMID: 41256904. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12621582/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.